E.U. Investigates Ozempic and Saxenda for Possible Link to Suicidal Thoughts

The European Medicines Agency (EMA) is investigating Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Saxenda after three cases of patients experiencing suicidal thoughts or self-harm were reported in Iceland. The EMA's safety committee is examining adverse events raised by the Icelandic Medicines Agency, including two cases of suicidal thoughts in individuals using Ozempic and Saxenda. Novo Nordisk stated that patient safety is their top priority and that their own safety monitoring has not found a causal association between the drugs and self-harming thoughts. The investigation also includes other medicines containing semaglutide or liraglutide, and the EMA may consider extending the review to other GLP-1 receptor agonists.